Please enter your license information:
CV Safety Outcomes
CARMELINA renal outcome events graph full text
- CARMELINA renal outcome events graph showing the demonstrated time to first occurrence of renal death, sustained end-stage renal disease, or sustained ≥40% decrease in eGFR (key secondary composite endpoint) for Trajenta® (n=3,494) and placebo (n=3,485).
- Y-axis shows the patients with event from 0 to 20%. Years from 0.0 to 3.5 is on the x-axis.
- The hazard ratio was 1.04 (95% confidence interval: 0.89 to 1.22), p=0.69. Subjects with events was 9.4% (n=327) for Trajenta® vs. 8.8% (n=306) for placebo.
- Patients at risk for placebo: 3,485 at Year 0.0, 3,213 at Year 0.5, 2,995 at Year 1.0, 2,298 at Year 1.5, 1,608 at Year 2.0, 1,005 at Year 2.5, 496 at Year 3.0 and 103 at Year 3.5.
- Patients at risk for Trajenta®: 3,494 at Year 0.0, 3,227 at Year 0.5, 3,018 at Year 1.0, 2,345 at Year 1.5, 1,675 at Year 2.0, 1,040 at Year 2.5, 518 at Year 3.0 and 109 at Year 3.5.
Are you thinking Trajenta®?
![Healthcare professional and patient Healthcare professional and patient](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/login-banner-updated.png)
Are you a Canadian
View coverage details for Trajenta® and Jentadueto®
![Map of Canada Map of Canada](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/check-coverage-icon.png)